RIPK1 and colorectal carcinoma: Treatment with human recombinant SORD has demonstrated inhibition of HCC cell growth as well as macrophage polarization.[137] In colorectal cancer (CRC) cell lines, truncation of DATE has been shown to activate hepatocyte growth factor (HGF) expression, thereby reducing receptor‐interacting protein kinase 1 (RIPK1) expression through mesenchymal epithelial transition (MET) signaling.